Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) had its price objective increased by investment analysts at Citizens Jmp from $92.00 to $93.00 in a research note issued to investors on Friday,Benzinga reports. Get Halozyme Therapeutics alerts:Get Our Latest Stock Analysis on Halozyme TherapeuticsHalozyme Therapeutics Trading Up 15.6%Shares of HALO traded up $13.42 during midday trading on Friday, reaching $99.18. Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. Featured StoriesReceive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.